General Information of Drug Off-Target (DOT) (ID: OTBG1FU4)

DOT Name Piezo-type mechanosensitive ion channel component 1 (PIEZO1)
Synonyms Membrane protein induced by beta-amyloid treatment; Mib; Protein FAM38A
Gene Name PIEZO1
Related Disease
Behcet disease ( )
PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis ( )
Acute myocardial infarction ( )
Adult respiratory distress syndrome ( )
Advanced cancer ( )
Alzheimer disease ( )
Arteriosclerosis ( )
Astrocytoma ( )
Atherosclerosis ( )
Autism spectrum disorder ( )
Bladder cancer ( )
Breast cancer ( )
Breast carcinoma ( )
Cardiac failure ( )
Chromosomal disorder ( )
Congestive heart failure ( )
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema ( )
Glioblastoma multiforme ( )
Glioma ( )
Hennekam lymphangiectasia-lymphedema syndrome 1 ( )
Lymphatic malformation 6 ( )
Malaria ( )
Meningioma ( )
Myocardial infarction ( )
Non-immune hydrops fetalis ( )
Osteoarthritis ( )
Osteoporosis ( )
Parkinson disease ( )
Prostate cancer ( )
Prostate carcinoma ( )
Rheumatoid arthritis ( )
Small lymphocytic lymphoma ( )
Type-1/2 diabetes ( )
Urinary bladder cancer ( )
Urinary bladder neoplasm ( )
Bacterial infection ( )
High blood pressure ( )
Krabbe disease ( )
Obesity ( )
Small-cell lung cancer ( )
Varicose veins ( )
Dehydrated hereditary stomatocytosis ( )
Adult glioblastoma ( )
Bone osteosarcoma ( )
Gastric cancer ( )
Hemolytic anemia ( )
Osteosarcoma ( )
Sickle-cell anaemia ( )
Stomach cancer ( )
Wilms tumor ( )
UniProt ID
PIEZ1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF15917 ; PF12166
Sequence
MEPHVLGAVLYWLLLPCALLAACLLRFSGLSLVYLLFLLLLPWFPGPTRCGLQGHTGRLL
RALLGLSLLFLVAHLALQICLHIVPRLDQLLGPSCSRWETLSRHIGVTRLDLKDIPNAIR
LVAPDLGILVVSSVCLGICGRLARNTRQSPHPRELDDDERDVDASPTAGLQEAATLAPTR
RSRLAARFRVTAHWLLVAAGRVLAVTLLALAGIAHPSALSSVYLLLFLALCTWWACHFPI
STRGFSRLCVAVGCFGAGHLICLYCYQMPLAQALLPPAGIWARVLGLKDFVGPTNCSSPH
ALVLNTGLDWPVYASPGVLLLLCYATASLRKLRAYRPSGQRKEAAKGYEARELELAELDQ
WPQERESDQHVVPTAPDTEADNCIVHELTGQSSVLRRPVRPKRAEPREASPLHSLGHLIM
DQSYVCALIAMMVWSITYHSWLTFVLLLWACLIWTVRSRHQLAMLCSPCILLYGMTLCCL
RYVWAMDLRPELPTTLGPVSLRQLGLEHTRYPCLDLGAMLLYTLTFWLLLRQFVKEKLLK
WAESPAALTEVTVADTEPTRTQTLLQSLGELVKGVYAKYWIYVCAGMFIVVSFAGRLVVY
KIVYMFLFLLCLTLFQVYYSLWRKLLKAFWWLVVAYTMLVLIAVYTFQFQDFPAYWRNLT
GFTDEQLGDLGLEQFSVSELFSSILVPGFFLLACILQLHYFHRPFMQLTDMEHVSLPGTR
LPRWAHRQDAVSGTPLLREEQQEHQQQQQEEEEEEEDSRDEGLGVATPHQATQVPEGAAK
WGLVAERLLELAAGFSDVLSRVQVFLRRLLELHVFKLVALYTVWVALKEVSVMNLLLVVL
WAFALPYPRFRPMASCLSTVWTCVIIVCKMLYQLKVVNPQEYSSNCTEPFPNSTNLLPTE
ISQSLLYRGPVDPANWFGVRKGFPNLGYIQNHLQVLLLLVFEAIVYRRQEHYRRQHQLAP
LPAQAVFASGTRQQLDQDLLGCLKYFINFFFYKFGLEICFLMAVNVIGQRMNFLVTLHGC
WLVAILTRRHRQAIARLWPNYCLFLALFLLYQYLLCLGMPPALCIDYPWRWSRAVPMNSA
LIKWLYLPDFFRAPNSTNLISDFLLLLCASQQWQVFSAERTEEWQRMAGVNTDRLEPLRG
EPNPVPNFIHCRSYLDMLKVAVFRYLFWLVLVVVFVTGATRISIFGLGYLLACFYLLLFG
TALLQRDTRARLVLWDCLILYNVTVIISKNMLSLLACVFVEQMQTGFCWVIQLFSLVCTV
KGYYDPKEMMDRDQDCLLPVEEAGIIWDSVCFFFLLLQRRVFLSHYYLHVRADLQATALL
ASRGFALYNAANLKSIDFHRRIEEKSLAQLKRQMERIRAKQEKHRQGRVDRSRPQDTLGP
KDPGLEPGPDSPGGSSPPRRQWWRPWLDHATVIHSGDYFLFESDSEEEEEAVPEDPRPSA
QSAFQLAYQAWVTNAQAVLRRRQQEQEQARQEQAGQLPTGGGPSQEVEPAEGPEEAAAGR
SHVVQRVLSTAQFLWMLGQALVDELTRWLQEFTRHHGTMSDVLRAERYLLTQELLQGGEV
HRGVLDQLYTSQAEATLPGPTEAPNAPSTVSSGLGAEEPLSSMTDDMGSPLSTGYHTRSG
SEEAVTDPGEREAGASLYQGLMRTASELLLDRRLRIPELEEAELFAEGQGRALRLLRAVY
QCVAAHSELLCYFIIILNHMVTASAGSLVLPVLVFLWAMLSIPRPSKRFWMTAIVFTEIA
VVVKYLFQFGFFPWNSHVVLRRYENKPYFPPRILGLEKTDGYIKYDLVQLMALFFHRSQL
LCYGLWDHEEDSPSKEHDKSGEEEQGAEEGPGVPAATTEDHIQVEARVGPTDGTPEPQVE
LRPRDTRRISLRFRRRKKEGPARKGAAAIEAEDREEEEGEEEKEAPTGREKRPSRSGGRV
RAAGRRLQGFCLSLAQGTYRPLRRFFHDILHTKYRAATDVYALMFLADVVDFIIIIFGFW
AFGKHSAATDITSSLSDDQVPEAFLVMLLIQFSTMVVDRALYLRKTVLGKLAFQVALVLA
IHLWMFFILPAVTERMFNQNVVAQLWYFVKCIYFALSAYQIRCGYPTRILGNFLTKKYNH
LNLFLFQGFRLVPFLVELRAVMDWVWTDTTLSLSSWMCVEDIYANIFIIKCSRETEKKYP
QPKGQKKKKIVKYGMGGLIILFLIAIIWFPLLFMSLVRSVVGVVNQPIDVTVTLKLGGYE
PLFTMSAQQPSIIPFTAQAYEELSRQFDPQPLAMQFISQYSPEDIVTAQIEGSSGALWRI
SPPSRAQMKRELYNGTADITLRFTWNFQRDLAKGGTVEYANEKHMLALAPNSTARRQLAS
LLEGTSDQSVVIPNLFPKYIRAPNGPEANPVKQLQPNEEADYLGVRIQLRREQGAGATGF
LEWWVIELQECRTDCNLLPMVIFSDKVSPPSLGFLAGYGIMGLYVSIVLVIGKFVRGFFS
EISHSIMFEELPCVDRILKLCQDIFLVRETRELELEEELYAKLIFLYRSPETMIKWTREK
E
Function
Pore-forming subunit of a mechanosensitive non-specific cation channel. Conductance to monovalent alkali ions is highest for K(+), intermediate for Na(+) and lowest for Li(+). Divalent ions except for Mn(2+) permeate the channel but more slowly than the monovalent ions and they also reduce K(+) currents. Generates currents characterized by a linear current-voltage relationship that are sensitive to ruthenium red and gadolinium. Plays a key role in epithelial cell adhesion by maintaining integrin activation through R-Ras recruitment to the ER, most probably in its activated state, and subsequent stimulation of calpain signaling. In the kidney, may contribute to the detection of intraluminal pressure changes and to urine flow sensing. Acts as a shear-stress sensor that promotes endothelial cell organization and alignment in the direction of blood flow through calpain activation. Plays a key role in blood vessel formation and vascular structure in both development and adult physiology. Acts as a sensor of phosphatidylserine (PS) flipping at the plasma membrane and governs morphogenesis of muscle cells. In myoblasts, flippase-mediated PS enrichment at the inner leaflet of plasma membrane triggers channel activation and Ca2+ influx followed by Rho GTPases signal transduction, leading to assembly of cortical actomyosin fibers and myotube formation.
Tissue Specificity
Expressed in numerous tissues. In normal brain, expressed exclusively in neurons, not in astrocytes. In Alzheimer disease brains, expressed in about half of the activated astrocytes located around classical senile plaques. In Parkinson disease substantia nigra, not detected in melanin-containing neurons nor in activated astrocytes. Expressed in erythrocytes (at protein level). Expressed in myoblasts (at protein level).

Molecular Interaction Atlas (MIA) of This DOT

50 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Behcet disease DISSYMBS Definitive Genetic Variation [1]
PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis DISXXP9R Definitive Autosomal recessive [2]
Acute myocardial infarction DISE3HTG Strong Altered Expression [3]
Adult respiratory distress syndrome DISIJV47 Strong Altered Expression [4]
Advanced cancer DISAT1Z9 Strong Altered Expression [5]
Alzheimer disease DISF8S70 Strong Altered Expression [6]
Arteriosclerosis DISK5QGC Strong Biomarker [7]
Astrocytoma DISL3V18 Strong Genetic Variation [8]
Atherosclerosis DISMN9J3 Strong Biomarker [7]
Autism spectrum disorder DISXK8NV Strong Genetic Variation [9]
Bladder cancer DISUHNM0 Strong Altered Expression [5]
Breast cancer DIS7DPX1 Strong Biomarker [10]
Breast carcinoma DIS2UE88 Strong Biomarker [10]
Cardiac failure DISDC067 Strong Altered Expression [11]
Chromosomal disorder DISM5BB5 Strong Biomarker [12]
Congestive heart failure DIS32MEA Strong Altered Expression [11]
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema DIS4WDHV Strong Autosomal dominant [2]
Glioblastoma multiforme DISK8246 Strong Biomarker [13]
Glioma DIS5RPEH Strong Biomarker [14]
Hennekam lymphangiectasia-lymphedema syndrome 1 DISB203L Strong Genetic Variation [15]
Lymphatic malformation 6 DISXFK12 Strong Autosomal recessive [16]
Malaria DISQ9Y50 Strong Genetic Variation [17]
Meningioma DISPT4TG Strong Biomarker [12]
Myocardial infarction DIS655KI Strong Altered Expression [11]
Non-immune hydrops fetalis DISPUY8C Strong Genetic Variation [15]
Osteoarthritis DIS05URM Strong Altered Expression [18]
Osteoporosis DISF2JE0 Strong Biomarker [19]
Parkinson disease DISQVHKL Strong Genetic Variation [20]
Prostate cancer DISF190Y Strong Biomarker [21]
Prostate carcinoma DISMJPLE Strong Biomarker [21]
Rheumatoid arthritis DISTSB4J Strong Genetic Variation [22]
Small lymphocytic lymphoma DIS30POX Strong Biomarker [23]
Type-1/2 diabetes DISIUHAP Strong Genetic Variation [24]
Urinary bladder cancer DISDV4T7 Strong Altered Expression [5]
Urinary bladder neoplasm DIS7HACE Strong Altered Expression [5]
Bacterial infection DIS5QJ9S moderate Biomarker [25]
High blood pressure DISY2OHH moderate Biomarker [26]
Krabbe disease DIS6H1IB moderate Genetic Variation [27]
Obesity DIS47Y1K moderate Biomarker [28]
Small-cell lung cancer DISK3LZD moderate Altered Expression [29]
Varicose veins DISIMBN2 moderate Genetic Variation [30]
Dehydrated hereditary stomatocytosis DISGQT6H Supportive Autosomal dominant [31]
Adult glioblastoma DISVP4LU Limited Biomarker [13]
Bone osteosarcoma DIST1004 Limited Biomarker [32]
Gastric cancer DISXGOUK Limited Altered Expression [33]
Hemolytic anemia DIS803XQ Limited Genetic Variation [24]
Osteosarcoma DISLQ7E2 Limited Biomarker [32]
Sickle-cell anaemia DIS5YNZB Limited Biomarker [34]
Stomach cancer DISKIJSX Limited Altered Expression [33]
Wilms tumor DISB6T16 Limited Altered Expression [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 50 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
5 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [36]
Arsenic DMTL2Y1 Approved Arsenic affects the methylation of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [41]
Fulvestrant DM0YZC6 Approved Fulvestrant increases the methylation of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [44]
PMID28870136-Compound-52 DMFDERP Patented PMID28870136-Compound-52 increases the phosphorylation of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [49]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the methylation of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [44]
------------------------------------------------------------------------------------
12 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [37]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [38]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [39]
Estradiol DMUNTE3 Approved Estradiol increases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [40]
Carbamazepine DMZOLBI Approved Carbamazepine affects the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [42]
Selenium DM25CGV Approved Selenium increases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [43]
Cerulenin DM6N4PR Approved Cerulenin affects the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [45]
Belinostat DM6OC53 Phase 2 Belinostat decreases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [46]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 decreases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [47]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 increases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [48]
Milchsaure DM462BT Investigative Milchsaure decreases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [50]
Hexadecanoic acid DMWUXDZ Investigative Hexadecanoic acid increases the expression of Piezo-type mechanosensitive ion channel component 1 (PIEZO1). [45]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Drug(s)

References

1 Analysis of microsatellite polymorphism around the HLA-B locus in Iranian patients with Behet's disease.Tissue Antigens. 2002 Nov;60(5):396-9. doi: 10.1034/j.1399-0039.2002.600506.x.
2 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
3 MiR-103a targeting Piezo1 is involved in acute myocardial infarction through regulating endothelium function.Cardiol J. 2016;23(5):556-562. doi: 10.5603/CJ.a2016.0056. Epub 2016 Aug 12.
4 Piezo1 induced apoptosis of type II pneumocytes during ARDS.Respir Res. 2019 Jun 11;20(1):118. doi: 10.1186/s12931-019-1083-1.
5 The increased expression of Piezo1 and Piezo2 ion channels in human and mouse bladder carcinoma.Adv Clin Exp Med. 2018 Aug;27(8):1025-1031. doi: 10.17219/acem/71080.
6 Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes.Front Aging Neurosci. 2018 Oct 22;10:332. doi: 10.3389/fnagi.2018.00332. eCollection 2018.
7 Piezo Ion Channels in Cardiovascular Mechanobiology.Trends Pharmacol Sci. 2019 Dec;40(12):956-970. doi: 10.1016/j.tips.2019.10.002. Epub 2019 Nov 5.
8 Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.J Neurooncol. 1999;44(3):255-66. doi: 10.1023/a:1006398613605.
9 HLA polymorphisms in Italian children with autism spectrum disorders: results of a family based linkage study.J Neuroimmunol. 2011 Jan;230(1-2):135-42. doi: 10.1016/j.jneuroim.2010.10.019. Epub 2010 Nov 17.
10 Piezo1 forms mechanosensitive ion channels in the human MCF-7 breast cancer cell line.Sci Rep. 2015 Feb 10;5:8364. doi: 10.1038/srep08364.
11 Stretch-activated channel Piezo1 is up-regulated in failure heart and cardiomyocyte stimulated by AngII.Am J Transl Res. 2017 Jun 15;9(6):2945-2955. eCollection 2017.
12 Chromosomal losses and gains in meningiomas: comparative genomic hybridization (CGH) study of the whole genome.Neurol Res. 1998 Oct;20(7):612-6. doi: 10.1080/01616412.1998.11740572.
13 A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression.Neuron. 2018 Nov 21;100(4):799-815.e7. doi: 10.1016/j.neuron.2018.09.046. Epub 2018 Oct 18.
14 Unlocking the Dangers of a Stiffening Brain.Neuron. 2018 Nov 21;100(4):763-765. doi: 10.1016/j.neuron.2018.11.011.
15 Author Correction: Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis.Nat Commun. 2019 Apr 26;10(1):1951. doi: 10.1038/s41467-019-09905-4.
16 The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
17 Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection.Cell. 2018 Apr 5;173(2):443-455.e12. doi: 10.1016/j.cell.2018.02.047. Epub 2018 Mar 22.
18 Mechanical exposure and diacerein treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes.Cell Signal. 2019 Apr;56:23-30. doi: 10.1016/j.cellsig.2018.12.010. Epub 2018 Dec 21.
19 The mechanosensitive Piezo1 channel is required for bone formation.Elife. 2019 Jul 10;8:e47454. doi: 10.7554/eLife.47454.
20 Overlapping genetic architecture between Parkinson disease and melanoma.Acta Neuropathol. 2020 Feb;139(2):347-364. doi: 10.1007/s00401-019-02110-z. Epub 2019 Dec 16.
21 Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle.Int J Oncol. 2019 Sep;55(3):629-644. doi: 10.3892/ijo.2019.4839. Epub 2019 Jul 15.
22 HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes.Scand J Rheumatol. 2002;31(5):275-8. doi: 10.1080/030097402760375160.
23 Characterization of sunburn cells after exposure to ultraviolet light.Photodermatol Photoimmunol Photomed. 1995 Aug;11(4):149-54. doi: 10.1111/j.1600-0781.1995.tb00157.x.
24 PIEZO1 gene mutation in a Japanese family with hereditary high phosphatidylcholine hemolytic anemia and hemochromatosis-induced diabetes mellitus.Int J Hematol. 2016 Jul;104(1):125-9. doi: 10.1007/s12185-016-1970-x. Epub 2016 Mar 14.
25 Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity.Nature. 2019 Sep;573(7772):69-74. doi: 10.1038/s41586-019-1485-8. Epub 2019 Aug 21.
26 Stretch-activated Piezo1 Channel in Endothelial Cells Relaxes Mouse Intrapulmonary Arteries.Am J Respir Cell Mol Biol. 2019 Jun;60(6):650-658. doi: 10.1165/rcmb.2018-0197OC.
27 Identification of novel PIEZO1 variants using prenatal exome sequencing and correlation to ultrasound and autopsy findings of recurrent hydrops fetalis.Am J Med Genet A. 2018 Dec;176(12):2829-2834. doi: 10.1002/ajmg.a.40533. Epub 2018 Sep 23.
28 Mechanosensitive Ion Channel Piezo1 Regulates Diet-Induced Adipose Inflammation and Systemic Insulin Resistance.Front Endocrinol (Lausanne). 2019 Jun 13;10:373. doi: 10.3389/fendo.2019.00373. eCollection 2019.
29 Loss of the integrin-activating transmembrane protein Fam38A (Piezo1) promotes a switch to a reduced integrin-dependent mode of cell migration.PLoS One. 2012;7(7):e40346. doi: 10.1371/journal.pone.0040346. Epub 2012 Jul 5.
30 Varicose veins of lower extremities: Insights from the first large-scale genetic study.PLoS Genet. 2019 Apr 18;15(4):e1008110. doi: 10.1371/journal.pgen.1008110. eCollection 2019 Apr.
31 Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood. 2012 Aug 30;120(9):1908-15. doi: 10.1182/blood-2012-04-422253. Epub 2012 Apr 23.
32 The Function of the Novel Mechanical Activated Ion Channel Piezo1 in the Human Osteosarcoma Cells.Med Sci Monit. 2017 Oct 24;23:5070-5082. doi: 10.12659/msm.906959.
33 PIEZO1 functions as a potential oncogene by promoting cell proliferation and migration in gastric carcinogenesis.Mol Carcinog. 2018 Sep;57(9):1144-1155. doi: 10.1002/mc.22831. Epub 2018 May 2.
34 Calcium Channels and Calcium-Regulated Channels in Human Red Blood Cells.Adv Exp Med Biol. 2020;1131:625-648. doi: 10.1007/978-3-030-12457-1_25.
35 Expression of MIB and BCL-2 in patients with nephrogenic rests with and without associated Wilms' tumors.Eur J Pediatr Surg. 2001 Apr;11(2):105-9. doi: 10.1055/s-2001-13783.
36 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
37 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
38 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
39 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
40 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
41 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
42 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
43 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
44 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
45 Exposure to dietary fatty acids oleic and palmitic acid alters structure and mechanotransduction of intestinal cells in vitro. Arch Toxicol. 2023 Jun;97(6):1659-1675. doi: 10.1007/s00204-023-03495-3. Epub 2023 Apr 29.
46 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
47 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
48 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
49 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
50 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.